‘How are these results even possible?’: Inside Rep. Chris Collins’ painful biotech education
'Wow. Makes no sense,'
by Damian Garde
Aug 08, 2018
3 minutes
Rep. Chris Collins was at the congressional picnic at the White House when he got the bad news.
It was June 22, 2017, and Innate Immunotherapeutics, an Australian biotech company in which he had heavily invested, was in a crisis. The company’s in-development drug, meant to treat multiple sclerosis, turned out to be no better than placebo in a large clinical trial. The study results were confidential, emailed only to Innate’s board of directors, of which Collins was a member.
“Wow. Makes no sense,” Collins replied to the board. “How are these
You’re reading a preview, subscribe to read more.
Start your free 30 days